Organization (Other)
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
ClinicalTrials.gov lists National Medical Research Center for Cardiology, Ministry of Health of Russian Federation as lead sponsor of 20 trials. It has 39 active development programs and 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers National Medical Research Center for Cardiology, Ministry of Health of Russian Federation: 20 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (42)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Atrial Fibrillation | 7 |
| Coronary Disease | 5 |
| Heart Failure | 5 |
| Myocardial Infarction | 5 |
| Coronary Artery Disease | 3 |
Showing 5 of 42 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 7 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 3 |
| 2015 | 2 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (39)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Oxacom | Hypertension, Pulmonary | Phase 2/3 | 1 |
| Oxacom | Pulmonary Arterial Hypertension | Phase 2/3 | 1 |
| [SGLTi + previously taken RAAS blocker] | Hypertrophy, Left Ventricular | Phase 2 | 1 |
| 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride | Atrial Flutter | Phase 2 | 1 |
| 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride | Atrial Fibrillation | Phase 2 | 1 |
Showing 5 of 39 active programs.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Pharmacological cardioversion with Refralon | 2 |
| Pharmacological cardioversion with Amiodarone | 1 |
| Single, weight-adjusted i.v. bolus of tenecteplase | 1 |
| Standard Care | 1 |
| EMPAGLIFLOZIN | 1 |
Showing 5 of 7 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 75% hit target (n=8) | 33% on time (n=6) |
Journals published in (31)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Terapevticheskii arkhiv | 14 |
| Kardiologiia | 7 |
| European heart journal | 5 |
| JACC. Cardiovascular interventions | 4 |
| Bulletin of experimental biology and medicine | 2 |
Showing 5 of 31 journals.
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| City Clinical Hospital No.52 of Moscow Healthcare Department | Co sponsors trial with | 1 |
| Sklifosovsky Institute of Emergency Care | Co sponsors trial with | 1 |
| Clinical City Hospital named after I.V. Davydovsky of Moscow Department of Healthcare | Co sponsors trial with | 1 |
| Meshalkin National Medical Research Center, Ministry of Health of Russian Federation | Co sponsors trial with | 1 |
| The Federal Centre of Cardiovascular Surgery, Russia | Co sponsors trial with | 1 |
Latest dated events (29)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-03-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-09-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 29 events.
Biomarker capability evidence (12)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| NPPB | Trial sponsor | Named in trial inclusion criteria |
| NPPB | Trial sponsor | Named in trial inclusion criteria |
| TTR | Trial sponsor | Named in trial inclusion criteria |
| PLAT | Trial sponsor | Named in trial exclusion criteria |
| SCAI | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 12 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.